• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot.
【24h】

Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot.

机译：使用ELISA和Western印迹检测来自SARS感染供体的血清中针对SARS-CoV的抗体。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recombinant fragments of S proteins from the Severe Acute Respiratory Syndrome (SARS) coronavirus (SARA-CoV) were generated and used in a Western blot (WB) assay that was compared to a commercial SARS ELISA method. In 85% of confirmed SARS cases (n = 20), the S2 recombinant fragment based WB was positive and this was comparable to the commercial ELISA using heat killed SARS-CoV. WB using the other four recombinant fragments in confirmed SARS cases generated lower rates of detection (S1-75%, S1-N-25%, S1-C-55%). Evaluation of sera from healthy controls (n = 60) resulted in two weakly positive ELISA results with the remainder being negative while the S2 protein WB demonstrated three positive results from the 20 controls with a history of SARS contact and no positive results in 40 noncontact controls. A discrepancy between the ELISA and S2 WB arose when evaluating per-2003 sera from individuals (n = 10) with SARS-like symptoms (ELISA-100% positive, S2 WB-30% positive). These data suggest that the S2 WB assay may be particularly useful in ELISA-negative SARS cases and in some ELISA-positive non-SARS cases.
机译：产生了来自严重急性呼吸系统综合症（SARS）冠状病毒（SARA-CoV）的S蛋白的重组片段，并将其用于与商用SARS ELISA方法进行比较的Western blot（WB）分析中。在85％确诊的SARS病例中（n = 20），基于S2重组片段的WB是阳性的，这与使用热灭活SARS-CoV的商业ELISA相当。在确诊的SARS病例中，WB使用其他四个重组片段产生的检出率较低（S1-75％，S1-N-25％，S1-C-55％）。对健康对照组（n = 60）的血清进行评估后，ELISA结果呈两个弱阳性，其余均为阴性，而S2蛋白WB证实了20个有SARS接触史的对照组中有3个阳性结果，而40个非接触性对照组中没有阳性结果。 。当评估患有SARS样症状（ELISA-100％阳性，S2 WB-30％阳性）的个体（n = 10）的2003年血清时，ELISA和S2 WB之间出现差异。这些数据表明，S2 WB分析在ELISA阴性SARS病例和某些ELISA阳性非SARS病例中可能特别有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号